The overall concordance rate was 90.74%; In detail, 86 cases were concordantly not amplified for HER2 in primary GC and corresponding nodal metastases, while 12 cases were HER2 amplified in both primitive and metastatic tumours (Table 2). The gene discussed is ERBB2; the disease is gastric cancer.